For patients with severe diarrhea or persistent diarrhea, or even dehydration, especially those with high risk factors (such as those who receive concurrent chemotherapy, have other symptoms or diseases, or have other basic factors including older age) , erlotinib therapy should be interrupted and appropriate measures should be taken to provide intravenous fluid rehydration to the patient. For dehydrated patients, renal function and blood electrolytes, including serum potassium, should be monitored while rehydrating. It is recommended to regularly monitor the renal function and serum electrolytes of patients at risk of dehydration (see [Adverse Reactions]).
Tarceva purchasing agent in India Tarceva purchasing agent Tarceva purchasing agent Tarceva in India